Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Multiple Sclerosis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Multiple Sclerosis
    TopAbstracts in Multiple Sclerosis 11/26/2009 - (DGNews)
    Women With MS No More Likely to Have Pregnancy Complications Than General Population - (DGNews)
    MS More Aggressive in Children but Slower to Cause Disability Than in Adults - (DGNews)
    TopAbstracts in Multiple Sclerosis 11/12/2009 - (DGNews)
    TopAbstracts in Multiple Sclerosis 10/29/2009 - (DGNews)

    News archive

     Recent webcasts/CME - Multiple Sclerosis
    • Selecting Immunomodulating Therapy in Relapsing-Remitting Multiple Sclerosis
    • Delaying the Conversion of Clinically Isolated Syndrome to Relapsing-Remitting Multiple Sclerosis Through Early Intervention With Disease-Modifying Therapy
    • Delaying Disease Progression in Patients With MS Who Become Nonresponsive to Established Disease-Modifying Therapies
    • Multiple Sclerosis: Tempering Disabilities and Decline--Fundamentals for Managed Markets
      Evidence-Based Update for NPs and PAs in the Diagnosis and Management of Multiple Sclerosis

      Webcasts/CME archive

       Recent cases - Multiple Sclerosis
        Encephalomyelitis Mimicking Multiple Sclerosis Associated with Chronic Graft-Versus-Host Disease after Allogeneic Bone Marrow Transplantation
        Progressive Primary Form of Multiple Sclerosis: Clinical and Radiological Improvement with Methylprednisolone in Continuous Pulsetherapy in One Case for 16 Years
        Burrowing of Urinary Bladder Wall by the Tip of a Size 22 Fr Silicone Foley Catheter in an Adult Male Patient With Multiple Sclerosis and Suprapubic Cystostomy: Should Caution be Exercised in Using a Size 22 Fr Silicone Foley Catheter for Long-Term Drainage of Neuropathic Bladder?
        Central Auditory Evaluation in Multiple Sclerosis: Case Report
        Recurrent Acute Hepatitis in Patient Receiving Pulsed Methylprednisolone for Multiple Sclerosis

        Cases archive
          




        my personal edition > multiple sclerosis > news
        divider

          E-Mail this DGDispatch to a colleague

        DGDispatch


        High-Dose Cyclophosphamide Achieves Rapid Clinical Improvements in Early, Aggressive Multiple Sclerosis: Presented at AAN

        By Claire Sowerbutt

        SAN DIEGO, C.A. -- April 6, 2006 -- Preliminary data from a study utilising 50 mg/kg/day of cyclophosphamide (HiCy) for 4 consecutive days suggest it is safe and provides rapid clinical and radiological improvements in patients with early, aggressive multiple sclerosis (MS).

        Peter Calabresi, MD, associate professor of neurology, Johns Hopkins University Hospital, Baltimore, Maryland, United States, presented the data here at the 58th Annual Meeting of the American Academy of Neurology (AAN).

        "This is a study using extremely high doses of cyclophosphamide, a drug that's been tested for many years, and used mostly in monthly pulse protocols," Dr. Calabresi said during his poster presentation on April 4th. "The concept came from our cancer center group, who has treated approximately 3000 patients with malignancies and about 200 patients with autoimmune diseases, but not MS."

        Patients who were entered into the open-label protocol had at least 2 gadolinium enhancing lesions present on magnetic resonance imaging, and 1 clinical exacerbation within the past year. They were on conventional MS therapy, yet had sustained increases of > 1.0 on the Expanded Disability Status Scale (EDSS).

        The protocol requires a 4-day hospitalisation period, after which participants became outpatients.

        "We've had no deaths on this protocol," Dr. Calabresi said.

        "Clinically, the results recapitulate what has been seen in other, aggressive bone marrow protocols, where patients with early, very active disease do very well. Their EDSS goes down, they stabilise for long periods of time," he explained.

        An advantage of the HiCy protocol, however, is that it does not require bone marrow stem cell transplantation. "We have found that the morbidity and mortality is much lower or nonexistent with this protocol, so it's extremely well tolerated and much cheaper because you don't have to harvest stem cells and give them back to the patient," he said.

        The results show reductions in lesions from baseline in all 8 patients. Additionally, 5 of the participants experienced sustained decreases in their EDSS following HiCy therapy, while 3 patients had similar or increased EDSS.

        "The patients who went into this study with high EDSS do not do well; they likely already had fixed damage" Dr. Calabresi said.

        "There were 2 patients that started out at 6.25 [EDSS] that continued to slowly progress, which tells us that if the disease is relatively advanced then this treatment is not worth the risk. If, however, it's relatively early stage disease, and worsening quickly, then this may be a therapeutic strategy," he said.

        Adverse events (AEs) and side effects related to treatment reported during the protocol include nausea, alopecia, anaemia, thrombocytopenia, leucopenia, loss of immunisation, febrile neutropenia, and amenorrhoea. No serious AEs have been reported to date; however, 1 patient has been hospitalised due to a suspected exacerbation.

        With respect to future plans for the protocol, Dr. Calabresi said, "We're now following the participants for 1 year, and we want to see what happens at 2 years."


        [Presentation title: High-Dose Cyclophosphamide in the Treatment of Aggressive Multiple Sclerosis. Poster PO1.072]



        E-Mail this DGDispatch to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send